Discuss this with your healthcare provider to make an informed decision
Based on treatment response and tolerability, the dose may be further increased at 30-day intervals to 9 mg, 14.5 mg, or the maximum of 17.2 mg
GLP-1 receptor agonist market, by product, 2021-2033 (USD Million) Table 14 U.S
FL: Data curation, Methodology, Validation, Visualization, Writing review & editing
If pharmaceutical innovators think, now is not the time to invest in gene therapy, in CAR T, in oncology programs, in rare and orphan and ultra rare diseases, thats bad news for patients, but its smart for financial investing, and you want financial investing and whats best for the patient to be on the same page
Published clinical trials on GLP-1 use in symptomatic gastroparesis populations are sparse, so decisions rely on case reports, mechanism-of-action understanding, and individual patient factors